ABIVAX SA · Data as of 2026-09-08
Q4 2026
As we look toward the upcoming Phase 3 maintenance trial readout in Q2 2026 and the Phase 2b ENHANCE-CD trial readout in Q4 2026, we remain focused on translating this data into real-world benefits for patients with IBD.Source filing
Q4 2026
The Company remains on track to submit its NDA to the U.S. Food and Drug Administration in the fourth quarter of 2026.Source filing
Mid-2027
• Mid-2027 – Topline results from the Phase 2b ENHANCE-CD induction trial evaluating obefazimod in Crohn's diseaseSource filing